To improve patient centricity in clinical development, we need to move past ‘gut-feeling’ and towards a data-led approach

Date: 10. 18. 2022

Clinical development has faced several years of disruption from recent global events, from the pandemic to the ongoing war in Ukraine and now a looming economic crisis. Given the scale of such events, it’s more important than ever to be able to accurately predict outcomes for clinical trials and minimize patient burden and R&D costs. This requires moving from a perception-led approach to a data-led approach. It means learning from the past and present by simulating the future. And designing smarter trials that lead to faster cures.

That’s why we’re excited to say that today, Phesi is launching its AI-based Trial Accelerator™ platform.

Based on the world’s most comprehensive and dynamic clinical development database, the platform delivers a new way of simulating trial outcomes and optimizing study design. It facilitates real-time ‘what if…?’ scenario modelling across patients, endpoints, country, KOL and investigator site allocation, and empowers clinical development personnel to make objective decisions based on real-world data.

By applying almost two decades of expertise in this space, Phesi saves customers an average of $7,000,000 per phase III trial. The platform also significantly reduces the risk of avoidable protocol amendments. Data from Tufts show that the average phase III protocol experiences 3.3 substantial amendments at a cost of $500,000 per amendment, Phesi’s Trial Accelerator™ can save sponsors up to $1,500,000 per trial in amendments alone.

By applying historical study data, including comparator arm data, to accurately simulate trial outcomes, the platform also enables planners to reduce the number of non-active/non-enrolling sites from 40% to less than 10%, adding up to further cost reduction. Our partners will also benefit by using the platform to create digital patient profiles, digital twins, and digital control arms (DCA) including external control arms. All of which is going to deliver on the industry’s most important objective – getting therapeutics to patients faster.

The Trial Accelerator™ uses fully integrated proprietary methods and AI models that have been created and validated over the past 15 years. Our customers have often requested access to Phesi data via a product in the hands of in-house staff and partners, so we’re delighted to meet this demand and put the power of patient-centric AI and analytics in the hands of teams.

There are many tools and services available that offer to support clinical trial planning and implementation. We are confident that our new platform distinguishes itself by leveraging data from more than 60 million patients in various settings. Historically, the industry has not had access to data at significant volume and with sufficient levels of context to allow predictive science. The Trial Accelerator™ changes that. Smarter trials, faster cures. Let’s embrace the future.

To find out how the Trial Accelerator™ can empower you to design smarter trials and develop faster cures and to book a demo visit

Related posts
10. 30. 2023
Zombies are for Hallowe’en, not for trials: Phesi launches new Health Check and Trial Rescue Service Read more
09. 25. 2023
Phesi: DPHARM Idol Disrupt nominee Read more
08. 20. 2023
Becoming a disruptive force for good in clinical development Read more
07. 10. 2023
Depression is moving up the clinical development agenda, but Phase II terminations are putting clinical development productivity in jeopardy Read more
06. 06. 2023
CAR-T Cytokine Release Syndrome: How can digital twins accelerate research? Read more
05. 16. 2023
Digital Patient Profile Catalog set to fast-track oncology clinical development Read more